UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for osteoporosis in the United Kingdom. Explore treatment pathways including bisphosphonates, anabolic agents, and novel therapies.
Osteoporosis affects ~3.5 million people in the UK, causing ~500,000 fragility fractures yearly. It weakens bones, making them break easily from minor falls or even coughing. Hip fractures alone cost the NHS ~£2 billion/year. Women are more affected (postmenopausal bone loss), but men get osteoporosis too. DEXA scans measure bone density and assess fracture risk using the FRAX tool.
First-line: oral bisphosphonates (alendronate, risedronate) - reduce fracture risk by ~50%. If intolerant: IV bisphosphonate (zoledronic acid, annual infusion) or denosumab (Prolia, 6-monthly injection). For high fracture risk: anabolic agents build new bone - teriparatide (daily injection, 2 years), romosozumab (Evenity, monthly injection, 1 year) followed by bisphosphonate to maintain gains. HRT (hormone replacement therapy) is an option for postmenopausal women.
Active UK osteoporosis trials include: novel anabolic agents, longer-acting bisphosphonates, new drug delivery methods, exercise interventions combined with medication, falls prevention programmes, vitamin D/calcium optimisation studies, and fracture liaison service models. The Royal Osteoporosis Society and NHS fracture liaison services support research across the UK.
Free AI-powered matching - no signup required
Search bone loss Trials →